ArticleEuropean stroke journal2023
European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy Endorsed by Vascular European Reference Network (VASCERN).
Article in European stroke journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Pooled it
- ESR Essentials: Perfusion MRI-practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology.European radiology · 2026Guideline
- Moyamoya disease in Southeast Asians: genetic and autopsy data, new cases, systematic review, and meta-analysis of all patients from the literature.Journal of neurology · 2024Pooled it
- Antiplatelet therapy may improve the prognosis of patients with moyamoya disease: a 12-year retrospective study.Journal of neurology · 2023Pooled it
- Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial.World journal of pediatrics : WJP · 2024Trial
- Multiterritorial tailored revascularization in adult Moyamoya patients: expanding revascularization approaches to ACA and PCA territories.Neurosurgical review · 2026Article
- Chinese expert consensus on the treatment and diagnosis of moyamoya disease and moyamoya syndrome (2024).Stroke and vascular neurology · 2026Article
- Emergency superficial temporal artery-middle cerebral artery bypass under dual antiplatelet therapy: an extreme salvage procedure for a misleading moyamoya case. Illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Vessel wall imaging in adult moyamoya disease with presumed acute in situ thrombotic occlusion: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- Moyamoya Disease in Pregnancy: A Case Series.AJP reports · 2026Article
- ALIGNED Network for rare cerebrovascular diseases: methodology and preliminary results.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Clinical Efficacy of Revascularization Surgery for Moyamoya Angiopathy: Long-Term Results of a European Cohort.European journal of neurology · 2026Article
- Flow-mediated pseudolesion mimicking an intracranial aneurysm secondary to cervical internal carotid artery dissection: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Effect of counseling on quality of life for children with Moyamoya disease and their caregivers.BMC nursing · 2026Article
- An Overview of Genetics of Moyamoya: BeyondInternational journal of molecular sciences · 2026Review
- Article
- Atorvastatin augments collateral formation and functional recovery after indirect revascularization in adult ischemic moyamoya disease: A randomized trial.Experimental and therapeutic medicine · 2026Article
- Development and validation of a risk prediction model for cerebral hyperperfusion syndrome after revascularization in adult moyamoya disease.Neurosurgical review · 2026Article
- European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.Orphanet journal of rare diseases · 2026Review
- Mode of Birth and Stroke Risk After Childbirth Among Women With Moyamoya Disease.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Stroke Organisation (ESO) guidelines on Moyamoya Angiopathy (MMA), developed according to ESO standard operating procedure and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, were compiled to assist clinicians in managing patients with MMA in their decision making. A working group involving neurologists, neurosurgeons, a geneticist and methodologists identified nine relevant clinical questions, performed systematic literature reviews and, whenever possible, meta-analyses. Quality assessment of the available evidence was made with specific recommendations. In the absence of sufficient evidence to provide recommendations, Expert Consensus Statements were formulated. Based on low quality evidence from one RCT, we recommend direct bypass surgery in adult patients with haemorrhagic presentation. For ischaemic adult patients and children, we suggest revascularization surgery using direct or combined technique rather than indirect, in the presence of haemodynamic impairment and with an interval of 6-12 weeks between the last cerebrovascular event and surgery. In the absence of robust trial, an Expert Consensus was reached recommending long-term antiplatelet therapy in non-haemorrhagic MMA, as it may reduce risk of embolic stroke. We also agreed on the utility of performing pre- and post- operative haemodynamic and posterior cerebral artery assessment. There were insufficient data to recommend systematic variant screening of RNF213 p.R4810K. Additionally, we suggest that long-term MMA neuroimaging follow up may guide therapeutic decision making by assessing the disease progression. We believe that this guideline, which is the first comprehensive European guideline on MMA management using GRADE methods will assist clinicians to choose the most effective management strategy for MMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.